The first vaccine to protect infants under 6 months of age and adults 60 years and older against respiratory syncytial virus (RSV) will soon be available in Europe, following marketing authorisation by the European Medicines Agency (EMA). Abrysvo (bivalent, recombinant, Pfizer) which received marketing approval by the U.S. Food & ...
First RSV Vaccine for Infants, Older Adults Approved for EU marketing
Liz Scherer
|
Medical News
|
21 July 2023
Register or log in to read more
Registration is free and easy, giving you complete access to all Univadis content.
Create a Free Account I have an account